Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2019

Open Access 01-12-2019 | Esophageal Cancer | Review

Genetic and molecular bases of esophageal Cancer among Iranians: an update

Authors: Mohammad Reza Abbaszadegan, Vahideh Keyvani, Meysam Moghbeli

Published in: Diagnostic Pathology | Issue 1/2019

Login to get access

Abstract

Background

Esophageal cancer is one of the leading causes of cancer related deaths among the Iranians. There is still a high ratio of mortality and low 5 years survival which are related to the late onset and diagnosis. Majority of patients refer for the treatment in advanced stages of tumor progression.

Main body

It is required to define an efficient local panel of diagnostic and prognostic markers for the Iranians. Indeed such efficient specific panel of markers will pave the way to decrease the mortality rate and increase the 5 years survival among the Iranian patients via the early diagnosis and targeted therapy.

Conclusion

in present review we have reported all of the molecular markers in different signaling pathways and cellular processes which have been assessed among the Iranian esophageal cancer patients until now.
Literature
1.
2.
Kamangar F, et al. Esophageal cancer in northeastern Iran: a review. Arch Iran Med. 2007;10(1):70–82.PubMed
3.
Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Physician. 2006;73(12):2187–94.PubMed
4.
Santibanez M, et al. Occupational exposures and risk of oesophageal cancer by histological type: a case-control study in eastern Spain. Occup Environ Med. 2008;65(11):774–81.CrossRefPubMed
5.
6.
Sepehr A, et al. Genetic polymorphisms in three Iranian populations with different risks of esophageal cancer, an ecologic comparison. Cancer Lett. 2004;213(2):195–202.CrossRefPubMed
7.
Islami F, Pourshmas A, Semnani S. Prevalence of esophageal cancer risk factors among Turkmen and non-Turkmen ethnic groups in a high incidence area in Iran. Arch Iran Med. 2010;13(2):111.PubMed
8.
Akbari MR, et al. Candidate gene association study of esophageal squamous cell carcinoma in a high-risk region in Iran. Cancer Res. 2009;69(20):7994–8000.CrossRefPubMedPubMedCentral
9.
Salehi Z, Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem. 2006;39(4):404–9.CrossRefPubMed
10.
Moghbeli M, et al. Clinicopathological sex- related relevance of musashi1 mRNA expression in esophageal squamous cell carcinoma patients. Pathol Oncol Res. 2014;20(2):427–33.CrossRefPubMed
11.
Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 2005;7(2):167–78.CrossRefPubMed
12.
Sedighi M, et al. Matrix Metalloproteinase-13 - a potential biomarker for detection and prognostic assessment of patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2016;17(6):2781–5.PubMed
13.
Golyan FF, Abbaszadegan MR, Forghanifard MM. TWIST1, MMP-21, and HLAG-1 co-overexpression is associated with ESCC aggressiveness. J Cell Biochem. 2019;120(9):14838-46.
14.
Salehi S, Jafarian AH, Forghanifard MM. Expression analysis of BRUCE protein in esophageal squamous cell carcinoma. Ann Diagn Pathol. 2016;24:47–51.CrossRefPubMed
15.
Abbaszadegan MR, et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol. 2008;14(13):2055–60.CrossRefPubMedPubMedCentral
16.
17.
Abbaszadegan MR, et al. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer. 2005;36(1):47–54.CrossRefPubMed
18.
Abedi-Ardekani B, et al. Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. PLoS One. 2011;6(12):e29488.CrossRefPubMedPubMedCentral
19.
Khalilipour N, et al. Familial esophageal squamous cell carcinoma with damaging rare/germline mutations in KCNJ12/KCNJ18 and GPRIN2 genes. Cancer Genet. 2018;221:46–52.CrossRefPubMed
20.
Forghanifard MM, et al. Role of DIDO1 in progression of esophageal squamous cell carcinoma. J Gastrointest Cancer. 2019:1–5. Epub ahead of print.
21.
Ghobadi N, et al. A genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma. J Cell Physiol. 2019;234(4):5070–6.CrossRefPubMed
22.
Hashemi Bidokhti M, et al. Contribution of MAML1 in esophageal squamous cell carcinoma tumorigenesis. Ann Diagn Pathol. 2017;27:79–82.CrossRefPubMed
23.
Forghanifard MM, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol. 2012;19(3):743–9.CrossRefPubMed
24.
Moghbeli M, et al. Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Med Oncol. 2013;30(2):516.CrossRefPubMed
25.
Forghanifard MM, et al. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma. Med Oncol. 2014;31(4):922.CrossRefPubMed
26.
Mahmoudian RA, et al. Biological and clinicopathological significance of Cripto-1 expression in the progression of human ESCC. Rep Biochem Mol Biol. 2017;5(2):83–90.PubMedPubMedCentral
27.
Mallak AJ, et al. Contribution of EVX1 in aggressiveness of esophageal squamous cell carcinoma. Pathol Oncol Res. 2016;22(2):341–7.CrossRefPubMed
28.
Forghanifard MM, Abbaszadegan MR, Moghbeli M. Role of SIZN1 in esophageal squamous cell carcinoma. Middle East J Cancer. 2019;10(1):37–42.
29.
Ansari MH, et al. Deregulation of miR-93 and miR-143 in human esophageal cancer. Tumour Biol. 2016;37(3):3097–103.CrossRefPubMed
30.
Ghasemi M, et al. Upregulation of miR-371–373 cluster, a human embryonic stem cell specific microRNA cluster, in esophageal squamous cell carcinoma. J Cancer Res Ther. 2018;14(Supplement):S132–7.PubMed
31.
Sahebi R, et al. Linc-ROR and its spliced variants 2 and 4 are significantly up-regulated in esophageal squamous cell carcinoma. Iran J Basic Med Sci. 2016;19(10):1131–5.PubMedPubMedCentral
32.
Maghsudlu, M., E. Farashahi Yazd, and T. Amiriani, Increased expression of MiR-27a and MiR-24-2 in esophageal squamous cell carcinoma. J Gastrointest Cancer, 2019:1-7. [Epub ahead of print].
33.
Akbari MR, et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene. 2008;27(9):1290–6.CrossRefPubMed
34.
Forghanifard MM, et al. Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther. 2011;12(3):191–7.CrossRefPubMed
35.
Liu T, et al. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma. Oncotarget. 2016;7(41):66851–64.PubMedPubMedCentral
36.
Battelli C, et al. The RNA-binding protein Musashi-1 regulates neural development through the translational repression of p21WAF-1. Mol Cell Neurosci. 2006;31(1):85–96.CrossRefPubMed
37.
Kawahara H, et al. Neural RNA-binding protein Musashi1 inhibits translation initiation by competing with eIF4G for PABP. J Cell Biol. 2008;181(4):639–53.CrossRefPubMedPubMedCentral
38.
Wang XY, et al. Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and notch pathways. Mol Cell Biol. 2008;28(11):3589–99.CrossRefPubMedPubMedCentral
39.
40.
Genasetti A, et al. Hyaluronan and human endothelial cell behavior. Connect Tissue Res. 2008;49(3):120–3.CrossRefPubMed
41.
Islami F, et al. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran - a review. Eur J Cancer. 2009;45(18):3156–65.CrossRefPubMed
42.
Aghcheli K, et al. Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers. Eur J Intern Med. 2012;23(1):58–64.CrossRefPubMed
43.
Cloosen S, et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol. 2006;135(4):513–6.CrossRefPubMed
44.
Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem. 2002;277(20):17616–22.CrossRefPubMed
45.
Kahkhaie KR, et al. Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer. World J Surg. 2014;38(8):2052–7.CrossRefPubMed
46.
Song ZB, et al. Expression of MUC1 in esophageal squamous-cell carcinoma and its relationship with prognosis of patients from Linzhou city, a high incidence area of northern China. World J Gastroenterol. 2003;9(3):404–7.CrossRefPubMedPubMedCentral
47.
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27.CrossRefPubMed
48.
Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Asp Med. 2008;29(5):290–308.CrossRef
49.
Eftekhary H, et al. The influence of matrix metalloproteinase-2, −9, and −12 promoter polymorphisms on Iranian patients with oesophageal squamous cell carcinoma. Contemp Oncol (Pozn). 2015;19(4):300–5.
50.
Zhao Z, et al. Increased MMP-21 expression in esophageal squamous cell carcinoma is associated with progression and prognosis. Med Oncol. 2014;31(8):91.CrossRefPubMed
51.
Bartke T, et al. Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol Cell. 2004;14(6):801–11.CrossRefPubMed
52.
Hao Y, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol. 2004;6(9):849–60.CrossRefPubMed
53.
Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem. 2005;280(1):174–82.CrossRefPubMed
54.
Tsuda H, et al. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol. 2003;91(3):476–85.CrossRefPubMed
55.
Jeannon JP, Wilson JA. Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer. Clin Otolaryngol Allied Sci. 1998;23(5):420–4.CrossRefPubMed
56.
Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer. 2006;106(3):483–93.CrossRefPubMed
57.
Fujiwara S, et al. Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas. Dis Esophagus. 2008;21(2):125–31.CrossRefPubMed
58.
Biramijamal F, et al. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res. 2001;61(7):3119–23.PubMed
59.
Souici AC, et al. Transition mutation in codon 248 of the p53 tumor suppressor gene induced by reactive oxygen species and a nitric oxide-releasing compound. Carcinogenesis. 2000;21(2):281–7.CrossRefPubMed
60.
Wink DA, et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis. 1998;19(5):711–21.CrossRefPubMed
61.
62.
63.
64.
Taghavi N, et al. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 2010;16(39):4958–67.CrossRefPubMedPubMedCentral
65.
Yao W, et al. Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(10):7158–63.PubMedPubMedCentral
66.
Kanamoto A, et al. No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol. 1999;72(2):94–8.CrossRefPubMed
67.
Akbari MR, et al. Familial risks of esophageal cancer among the Turkmen population of the Caspian littoral of Iran. Int J Cancer. 2006;119(5):1047–51.CrossRefPubMed
68.
69.
Lin SE, et al. Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling. J Biol Chem. 2002;277(52):50612–20.CrossRefPubMed
70.
Wu L, et al. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol. 2002;22(21):7688–700.CrossRefPubMedPubMedCentral
71.
Ansieau S, et al. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene. 2010;29(22):3173–84.CrossRefPubMed
72.
Yeo SY, et al. Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance. Oncotarget. 2017;8(39):65265–80.CrossRefPubMedPubMedCentral
73.
Lee KW, et al. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol. 2012;19(1):326–35.CrossRefPubMed
74.
Bienz M. Beta-catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol. 2005;15(2):R64–7.CrossRefPubMed
75.
76.
Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 2005;32(1):52–60.CrossRefPubMed
77.
Moghbeli M, et al. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49–53.CrossRefPubMed
78.
79.
Li JC, et al. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma. Tumour Biol. 2014;35(1):651–7.CrossRefPubMed
80.
Hoshino M, et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology. 2007;74(1):15–21.CrossRefPubMed
81.
Fong H, Hohenstein KA, Donovan PJ. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells. 2008;26(8):1931–8.CrossRefPubMed
82.
Yuri S, et al. Sall4 is essential for stabilization, but not for pluripotency, of embryonic stem cells by repressing aberrant trophectoderm gene expression. Stem Cells. 2009;27(4):796–805.CrossRefPubMed
83.
Chuang WY, Chang YS, Chao YK, Yeh CJ, Liu YH, Tseng CK, Chang HK, Wan YL, Hsueh C. High sex determining region Y-box 2 (SOX2) expression correlates with absence of nodal metastasis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(8):9248.
84.
Bianco C, et al. Activation of a nodal-independent signaling pathway by Cripto-1 mutants with impaired activation of a nodal-dependent signaling pathway. FEBS Lett. 2008;582(29):3997–4002.CrossRefPubMedPubMedCentral
85.
Bianco C, et al. A nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res. 2003;63(6):1192–7.PubMed
86.
Klauzinska M, et al. The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition. Semin Cancer Biol. 2014;29:51–8.CrossRefPubMed
87.
88.
Liu Q, et al. Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma. Mol Cancer. 2017;16(1):81.CrossRefPubMedPubMedCentral
89.
Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009;19(1):71–88.CrossRefPubMed
90.
Cai M, et al. Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation. Blood. 2012;120(2):335–46.CrossRefPubMedPubMedCentral
91.
Rad A, et al. Predicting the molecular role of MEIS1 in esophageal squamous cell carcinoma. Tumour Biol. 2016;37(2):1715–25.CrossRefPubMed
92.
Moghbeli M, et al. Correlation between Meis1 and Msi1 in esophageal squamous cell carcinoma. J Gastrointest Cancer. 2016;47(3):273–7.CrossRefPubMed
93.
Abbaszadegan MR, Moghbeli M. Role of MAML1 and MEIS1 in esophageal squamous cell carcinoma depth of invasion. Pathol Oncol Res. 2018;24(2):245–50.CrossRefPubMed
94.
95.
Noguchi S, et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 2011;307(2):211–20.CrossRefPubMed
96.
Xu B, et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011;350(1–2):207–13.CrossRefPubMed
97.
Chen X, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–92.CrossRefPubMed
98.
99.
100.
Ni Y, et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene. 2013;517(2):197–204.CrossRefPubMed
101.
Zhou AD, et al. Beta-catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway. Oncogene. 2012;31(24):2968–78.CrossRefPubMed
102.
Voorhoeve PM, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol. 2007;604:17–46.CrossRefPubMed
103.
Tian Y, et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. Int J Oncol. 2012;40(4):1105–12.PubMed
104.
Liu N, et al. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013;12(1):123.CrossRefPubMedPubMedCentral
105.
Khazaei S, et al. A novel signaling role for miR-451 in esophageal tumor microenvironment and its contribution to tumor progression. Clin Transl Oncol. 2017;19(5):633–40.CrossRefPubMed
106.
107.
108.
Hou P, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5:e1287.CrossRefPubMedPubMedCentral
109.
Zhang A, et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2013;23(3):340–50.CrossRefPubMed
110.
Shahryari A, et al. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma. Stem Cells. 2014;32(1):126–34.CrossRefPubMed
111.
Ba S, et al. MicroRNA-27a promotes the proliferation and invasiveness of colon cancer cells by targeting SFRP1 through the Wnt/beta-catenin signaling pathway. Cell Physiol Biochem. 2017;42(5):1920–33.CrossRefPubMed
112.
113.
Marmorstein LY, et al. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell. 2001;104(2):247–57.CrossRefPubMed
114.
An JY, et al. Loss of heterozygosity in multistage carcinogenesis of esophageal carcinoma at high-incidence area in Henan province, China. World J Gastroenterol. 2005;11(14):2055–60.CrossRefPubMedPubMedCentral
115.
Hung CM, et al. Developing informative microsatellite makers for non-model species using reference mapping against a model species’ genome. Sci Rep. 2016;6:23087.CrossRefPubMedPubMedCentral
116.
Sturzeneker R, et al. Microsatellite instability in tumors as a model to study the process of microsatellite mutations. Hum Mol Genet. 2000;9(3):347–52.CrossRefPubMed
117.
Forghanifard MM, et al. Loss of heterozygosity and microsatellite instability as predictive markers among Iranian esophageal cancer patients. Iran J Basic Med Sci. 2016;19(7):726–33.PubMedPubMedCentral
118.
Uehara H, et al. Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol. 2005;92(2):109–15.CrossRefPubMed
119.
120.
121.
Sakurai T, et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem. 2004;279(15):15505–14.CrossRefPubMed
122.
Haier J, et al. Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res. 2006;26(3B):2281–7.PubMed
123.
Qi Y, et al. High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma. Oncol Lett. 2017;14(3):3415–20.CrossRefPubMedPubMedCentral
Metadata
Title
Genetic and molecular bases of esophageal Cancer among Iranians: an update
Authors
Mohammad Reza Abbaszadegan
Vahideh Keyvani
Meysam Moghbeli
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2019
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0875-4

Other articles of this Issue 1/2019

Diagnostic Pathology 1/2019 Go to the issue

Case Report

Splenic cord capillary hemangioma with non-islet cell tumor hypoglycemia: a case report

Case Report

Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report

Research

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China

Research

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma

Research

Updated Oxford classification and the international study of kidney disease in children classification: application in predicting outcome of Henoch-Schönlein purpura nephritis

Short report

Improving sensitivity of amyloid detection by Congo red stain by using polarizing microscope and avoiding pitfalls